Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

BACKGROUND: Radioligand therapy (RLT) with (177)Lu-DKFZ-617 PSMA (Lu-PSMA) (prostate-specific membrane antigen) is a novel targeted therapy of metastatic prostate cancer. We analysed retrospectively the early side effects and the response rate in the first patients, who received a therapy with Lu-PS...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmadzadehfar, Hojjat, Rahbar, Kambiz, Kürpig, Stefan, Bögemann, Martin, Claesener, Michael, Eppard, Elisabeth, Gärtner, Florian, Rogenhofer, Sebastian, Schäfers, Michael, Essler, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477007/
https://www.ncbi.nlm.nih.gov/pubmed/26099227
http://dx.doi.org/10.1186/s13550-015-0114-2

Ejemplares similares

Ejemplares similares